Earnings rebound at Nu Skin (NYSE: NUS) as 2025 EPS hits $3.18
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Nu Skin Enterprises reported fourth-quarter and full-year 2025 results within guidance, with profitability improving despite lower sales. 2025 revenue was $1.49 billion, down 14.3% from 2024, while diluted EPS rose to $3.18 (or $1.27 excluding the Mavely gain and other charges) from a loss of $(2.95).
Fourth-quarter revenue was $370.3 million, down 16.9%, but EPS improved to $0.29 from $(0.73) as gross margin expanded and restructuring costs fell. Customers declined 10%, and sales leaders fell 19%. For 2026, the company guides revenue to $1.35–$1.50 billion and EPS of $0.80–$1.20, expecting a return to year-over-year revenue growth by year-end driven by its Prysm iO wellness platform and an anticipated India market launch.
Positive
- None.
Negative
- None.
Insights
Profit rebounded on margins and one-time gains, but revenue and leader counts are under pressure.
Nu Skin delivered 2025 EPS of
However, top line trends are weak. Revenue fell 14.3% to
Guidance implies another transition year. Management forecasts 2026 revenue of
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
||
|
Date of Report (Date of earliest event reported)
|
||
|
|
||
|
(Exact name of registrant as specified in its charter)
|
|
|
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
|
||
|
(Address of principal executive offices and zip code)
|
||
|
(
|
||
|
(Registrant’s telephone number, including area code)
|
||
|
N/A
|
||
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 |
Results of Operations and Financial Condition.
|
On February 12, 2026, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month and annual periods ended
December 31, 2025, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.
The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
| 99.1 |
Nu Skin Enterprises’ press release dated February 12, 2026, regarding financial results for the three-month and annual periods ended December 31, 2025.
|
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
NU SKIN ENTERPRISES, INC.
|
||
|
(Registrant)
|
||
|
/s/ James D. Thomas
|
||
|
James D. Thomas
|
||
|
Chief Financial Officer
|
||
|
Date: February 12, 2026
|
||
Exhibit 99.1
FOR IMMEDIATE RELEASE
Nu Skin Enterprises Reports Fourth Quarter and Full-year 2025 Results
Within Guidance
Company provides initial outlook for Q1 and fiscal year 2026, forecasting a return to revenue growth by year’s end
PROVO, Utah — Feb. 12, 2026 — Nu Skin
Enterprises Inc. (NYSE: NUS) today announced fourth quarter and full-year 2025 revenue and earnings within guidance with more than 50% growth in earnings for 2025.
Executive Summary
Q4 2025 vs. Prior-year Quarter
|
Revenue
|
$370.3 million; (16.9)% or (10.4)% excluding Mavely 2024 revenue
• (0.2)% FX
impact or $(0.8) million
|
||
|
Earnings Per Share
(EPS)
|
$0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges
|
||
|
Customers
|
748,796; (10)%
|
||
|
Paid Affiliates
|
129,311; (11)%
|
||
|
Sales Leaders
|
30,045; (19)%
|
Executive Summary
2025 vs. 2024
|
Revenue:
|
$1.49 billion; (14.3)% or (10.7%) excluding Mavely 2024 revenue
• (0.8)% FX
impact or $(13.4) million
|
||
|
Earnings Per Share
(EPS):
|
$3.18 or $1.27 excluding Mavely gain and other charges compared to $(2.95) or $0.84 excluding restructuring and other charges
|
“We are pleased to achieve fourth quarter results within our guidance range for both revenue and earnings per share,” said Ryan Napierski, Nu
Skin president and CEO. “This past year was a pivotal year as we furthered our transformation toward becoming the world’s leading intelligent beauty and wellness platform and laid the groundwork for our 2026 growth initiatives. Looking ahead, we
continue to build sales leader alignment in the first half of the year around the global launch of Prysm iO, positioning us for a return to year-over-year revenue growth by year’s end.
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 2
|
“We are now placing Prysm iO intelligent wellness devices into the hands of sales leaders around the world ahead of our consumer launch in the
second half of the year. More than 20,000 devices are already in the hands of our sales leaders generating more than 700,000 scans. As we gain greater adoption and more individuals are scanning and receiving their personalized product
recommendations, we anticipate this will drive growth in subscriptions leading to greater customer lifetime value. We have also begun pre-market activities in India, setting the operational foundation and infrastructure ahead of a full market
opening anticipated in the back half of the year. Overall, we are encouraged by the progress we are making and believe these two initiatives give us the greatest opportunity for sustainable, long-term growth and increased shareholder value.”
Q4 2025 Year-over-year Operating Results
|
Revenue
|
$370.3 million compared to $445.6 million or $413.3 million excluding Mavely 2024 revenue
• (0.2)% FX
impact or $(0.8) million
|
||
|
Gross Margin
|
70.7% compared to 62.7% or 71.4% excluding inventory write-off
• Nu Skin
business was 77.6% compared to 67.5% or 76.6% excluding inventory write-off
|
||
|
Selling Expenses
|
35.5% compared to 37.1%
• Nu Skin
business was 40.8% compared to 40.3%
|
||
|
G&A Expenses
|
29.0% compared to 27.1%
|
||
|
Operating Margin
|
6.3% compared to (11.9)% or 7.7% excluding restructuring and other charges
|
||
|
Interest Expense
|
$4.0 million compared to $5.9 million
|
||
|
Other Income
(Expense)
|
$(1.1) million compared to $1.1 million
|
||
|
Income Tax Rate
|
20.3% compared to 37.5% or 36.6% excluding restructuring and other charges
|
||
|
EPS
|
$0.29 compared to $(0.73) or $0.38 excluding restructuring and other charges
|
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 3
|
Stockholder Value
|
Dividend Payments
|
$2.9 million
|
||
|
Stock Repurchases
|
$10.0 million
• $142.3 million
remaining in authorization
|
Q1 and Full-year 2026 Outlook
|
Q1 2026 Revenue
|
$320 to $340 million; (12)% to (7)%
• Approximately (1)% FX impact
|
||
|
Q1 2026 EPS
|
$0.10 to $0.20
|
||
|
2026 Revenue
|
$1.35 to $1.50 billion; (9)% to 1%
• Approximately
(1)% FX impact
|
||
|
2026 EPS
|
$0.80 to $1.20
|
“We are pleased with how we performed this year, growing earnings by more than 50% due to effective margin improvement and cost optimization
amidst top-line pressures,” said James D. Thomas, chief financial officer. “As we look to return to year-over-year growth by year’s end, our annual revenue guidance is $1.35 to $1.50 billion, with an approximate 1% foreign currency headwind. We
anticipate EPS of $0.80 to $1.20 with a forecasted tax rate of 35%. For the first quarter, which is typically our lowest quarter due to seasonality of our business, we project revenue of $320 to $340 million. This assumes a negative foreign
currency impact of approximately 1%. We project earnings per share of $0.10 to $0.20.”
Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the
webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company’s website at ir.nuskin.com. A replay of the webcast will be available on the same page through Feb. 26, 2026.
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 4
|
About Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly
50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device
systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within
the beauty, wellness and lifestyle categories.
Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the
company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of
management’s expectations regarding the company’s performance, growth, and growth opportunities and initiatives, shareholder value, transformation, the Prysm launch and its potential benefits to the business, and new market expansion and its
timing; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying
any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “become,” “continue,” “project,” “outlook,” “guidance,” “will,” “would,” “could,” “may,” “might,” the negative of these
words and other similar words.
The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ
materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:
| • |
any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on
a sustained basis;
|
| • |
risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a
manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales
force actions, imposition of fines, or any other adverse actions or events;
|
| • |
economic conditions and events globally;
|
| • |
the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets,
and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;
|
| • |
competitive pressures in the company’s markets;
|
| • |
risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;
|
| • |
adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
|
| • |
political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
|
| • |
uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business
operations and results;
|
| • |
risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
|
| • |
uncertainties regarding the future financial performance of the businesses the company has acquired;
|
| • |
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of
inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and
|
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 5
|
| • |
regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in
a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.
|
The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated
risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no
duty to update the forward-looking statements contained in this release to reflect any change except as required by law.
Non-GAAP Financial Measures:
Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by
translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue
change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.
Earnings per share, gross margin, operating margin and income tax rate, each excluding inventory write-off charges, restructuring and impairment
expense, the gain from the Mavely sale, unrealized investment loss, and/or other charges, as well as revenue growth rate excluding Mavely 2024 revenue, also are non-GAAP financial measures.
| • |
Inventory write-off charges, restructuring and impairment expense, and unrealized investment loss are not part of the ongoing operations of our underlying business;
|
| • |
the gain from the Mavely sale and the other charges incurred in connection with this sale that have been excluded in the non-GAAP financial measures are not typical for our
ongoing operations; and
|
| • |
Mavely revenue is no longer included in our operations following our sale of this business on January 2, 2025.
|
The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these
items facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP,
below.
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 6
|
The following table sets forth revenue for the three-month periods ended December 31, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands):
|
Three Months Ended
December 31,
|
Constant-Currency
|
|||||||||||||||
|
2025
|
2024
|
Change
|
Change
|
|||||||||||||
|
Nu Skin
|
||||||||||||||||
|
Americas
|
$
|
76,977
|
$
|
85,356
|
(9.8
|
)%
|
(4.5
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
50,210
|
64,925
|
(22.7
|
)%
|
(22.9
|
)%
|
||||||||||
|
Mainland China
|
52,035
|
56,438
|
(7.8
|
)%
|
(9.0
|
)%
|
||||||||||
|
Japan
|
42,504
|
47,512
|
(10.5
|
)%
|
(9.5
|
)%
|
||||||||||
|
Europe & Africa
|
41,800
|
42,600
|
(1.9
|
)%
|
(10.2
|
)%
|
||||||||||
|
South Korea
|
28,431
|
33,423
|
(14.9
|
)%
|
(11.8
|
)%
|
||||||||||
|
Hong Kong/ Taiwan
|
29,605
|
32,549
|
(9.0
|
)%
|
(11.6
|
)%
|
||||||||||
|
Other
|
239
|
(354
|
)
|
167.5
|
%
|
171.1
|
%
|
|||||||||
|
Total Nu Skin
|
321,801
|
362,449
|
(11.2
|
)%
|
(11.0
|
)%
|
||||||||||
|
Rhyz
|
||||||||||||||||
|
Manufacturing
|
42,451
|
47,882
|
(11.3
|
)%
|
(11.3
|
)%
|
||||||||||
|
Rhyz Other
|
6,068
|
35,221
|
(82.8
|
)%
|
(82.8
|
)%
|
||||||||||
|
Total Rhyz
|
48,519
|
83,103
|
(41.6
|
)%
|
(41.6
|
)%
|
||||||||||
|
Total
|
$
|
370,320
|
$
|
445,552
|
(16.9
|
)%
|
(16.7
|
)%
|
||||||||
The following table sets forth revenue for the years ended December 31, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands):
|
Year Ended
December 31,
|
Constant-Currency
|
|||||||||||||||
|
2025
|
2024
|
Change
|
Change
|
|||||||||||||
|
Nu Skin
|
||||||||||||||||
|
Americas
|
$
|
282,975
|
$
|
322,516
|
(12.3
|
)%
|
(6.2
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
209,802
|
244,846
|
(14.3
|
)%
|
(14.6
|
)%
|
||||||||||
|
Mainland China
|
195,553
|
235,235
|
(16.9
|
)%
|
(16.9
|
)%
|
||||||||||
|
Japan
|
174,364
|
181,557
|
(4.0
|
)%
|
(5.1
|
)%
|
||||||||||
|
Europe & Africa
|
150,151
|
164,164
|
(8.5
|
)%
|
(12.6
|
)%
|
||||||||||
|
South Korea
|
130,216
|
163,706
|
(20.5
|
)%
|
(17.1
|
)%
|
||||||||||
|
Hong Kong/ Taiwan
|
117,378
|
130,610
|
(10.1
|
)%
|
(11.9
|
)%
|
||||||||||
|
Other
|
1,138
|
2,832
|
(59.8
|
)%
|
(48.5
|
)%
|
||||||||||
|
Total Nu Skin
|
1,261,577
|
1,445,466
|
(12.7
|
)%
|
(11.8
|
)%
|
||||||||||
|
Rhyz
|
||||||||||||||||
|
Manufacturing
|
205,788
|
201,430
|
2.2
|
%
|
2.2
|
%
|
||||||||||
|
Rhyz Other
|
17,794
|
85,188
|
(79.1
|
)%
|
(79.1
|
)%
|
||||||||||
|
Total Rhyz
|
223,582
|
286,618
|
(22.0
|
)%
|
(22.0
|
)%
|
||||||||||
|
Total
|
$
|
1,485,159
|
$
|
1,732,084
|
(14.3
|
)%
|
(13.5
|
)%
|
||||||||
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 7
|
The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month
periods ended December 31, 2025, and 2024:
|
Three Months Ended
December 31,
|
||||||||||||
|
2025
|
2024
|
Change
|
||||||||||
|
Customers
|
||||||||||||
|
Americas
|
225,527
|
227,556
|
(1
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
74,300
|
82,956
|
(10
|
)%
|
||||||||
|
Mainland China
|
118,523
|
150,731
|
(21
|
)%
|
||||||||
|
Japan
|
104,439
|
110,069
|
(5
|
)%
|
||||||||
|
Europe & Africa
|
127,910
|
133,306
|
(4
|
)%
|
||||||||
|
South Korea
|
58,880
|
81,301
|
(28
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
39,217
|
46,053
|
(15
|
)%
|
||||||||
|
Total
|
748,796
|
831,972
|
(10
|
)%
|
||||||||
|
Paid Affiliates
|
||||||||||||
|
Americas
|
28,900
|
28,361
|
2
|
%
|
||||||||
|
Southeast Asia/Pacific
|
20,260
|
26,310
|
(23
|
)%
|
||||||||
|
Mainland China
|
18,922
|
22,125
|
(14
|
)%
|
||||||||
|
Japan
|
20,126
|
22,318
|
(10
|
)%
|
||||||||
|
Europe & Africa
|
14,918
|
16,860
|
(12
|
)%
|
||||||||
|
South Korea
|
16,341
|
17,939
|
(9
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
9,844
|
10,961
|
(10
|
)%
|
||||||||
|
Total
|
129,311
|
144,874
|
(11
|
)%
|
||||||||
|
Sales Leaders
|
||||||||||||
|
Americas
|
6,016
|
6,778
|
(11
|
)%
|
||||||||
|
Southeast Asia/Pacific
|
4,272
|
5,288
|
(19
|
)%
|
||||||||
|
Mainland China
|
6,065
|
8,969
|
(32
|
)%
|
||||||||
|
Japan
|
6,259
|
6,780
|
(8
|
)%
|
||||||||
|
Europe & Africa
|
2,722
|
3,343
|
(19
|
)%
|
||||||||
|
South Korea
|
2,547
|
3,343
|
(24
|
)%
|
||||||||
|
Hong Kong/Taiwan
|
2,164
|
2,411
|
(10
|
)%
|
||||||||
|
Total
|
30,045
|
36,912
|
(19
|
)%
|
||||||||
| ● |
“Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such
a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
|
| ● |
“Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides
Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.
|
| ● |
“Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification
requirements as of the end of each month of the quarter.
|
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 8
|
NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Revenue
|
$
|
370,320
|
$
|
445,552
|
$
|
1,485,159
|
$
|
1,732,084
|
||||||||
|
Cost of sales
|
108,339
|
166,405
|
453,761
|
550,233
|
||||||||||||
|
Gross profit
|
261,981
|
279,147
|
1,031,398
|
1,181,851
|
||||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Selling expenses
|
131,342
|
165,422
|
508,380
|
652,039
|
||||||||||||
|
General and administrative expenses
|
107,395
|
120,930
|
432,141
|
479,037
|
||||||||||||
|
Restructuring and impairment expenses
|
—
|
45,876
|
25,114
|
202,360
|
||||||||||||
|
Total operating expenses
|
238,737
|
332,228
|
965,635
|
1,333,436
|
||||||||||||
|
Operating income (loss)
|
23,244
|
(53,081
|
)
|
65,763
|
(151,585
|
)
|
||||||||||
|
Interest expense
|
3,994
|
5,864
|
13,948
|
26,409
|
||||||||||||
|
Gain on sale
|
—
|
—
|
176,162
|
—
|
||||||||||||
|
Other income (expense), net
|
(1,059
|
)
|
1,143
|
(31,780
|
)
|
2,943
|
||||||||||
|
Income (loss) before provision for income taxes
|
18,191
|
(57,802
|
)
|
196,197
|
(175,051
|
)
|
||||||||||
|
Provision (benefit) for income taxes
|
3,700
|
(21,697
|
)
|
35,993
|
(28,457
|
)
|
||||||||||
|
Net income (loss)
|
$
|
14,491
|
$
|
(36,105
|
)
|
$
|
160,204
|
$
|
(146,594
|
)
|
||||||
|
Net income (loss) per share:
|
||||||||||||||||
|
Basic
|
$
|
0.30
|
$
|
(0.73
|
)
|
$
|
3.25
|
$
|
(2.95
|
)
|
||||||
|
Diluted
|
$
|
0.29
|
$
|
(0.73
|
)
|
$
|
3.18
|
$
|
(2.95
|
)
|
||||||
|
Weighted-average common shares outstanding (000s):
|
||||||||||||||||
|
Basic
|
48,581
|
49,712
|
49,293
|
49,662
|
||||||||||||
|
Diluted
|
49,912
|
49,712
|
50,301
|
49,662
|
||||||||||||
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 9
|
NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
ASSETS
|
||||||||
|
Current assets
|
||||||||
|
Cash and cash equivalents
|
$
|
238,630
|
$
|
186,883
|
||||
|
Current investments
|
1,211
|
11,111
|
||||||
|
Accounts receivable, net
|
39,544
|
50,784
|
||||||
|
Inventories, net
|
178,643
|
190,242
|
||||||
|
Prepaid expenses and other
|
89,670
|
72,643
|
||||||
|
Current assets held for sale
|
—
|
26,936
|
||||||
|
Total current assets
|
547,698
|
538,599
|
||||||
|
Property and equipment, net
|
377,168
|
379,595
|
||||||
|
Operating lease right-of-use assets
|
74,021
|
72,605
|
||||||
|
Goodwill
|
83,625
|
83,625
|
||||||
|
Other intangible assets, net
|
42,614
|
74,278
|
||||||
|
Other assets
|
280,187
|
298,008
|
||||||
|
Long-term assets held for sale
|
—
|
22,204
|
||||||
|
Total assets
|
$
|
1,405,313
|
$
|
1,468,914
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable
|
$
|
26,183
|
$
|
34,880
|
||||
|
Accrued expenses
|
217,551
|
217,808
|
||||||
|
Current portion of long-term debt
|
20,000
|
30,000
|
||||||
|
Current liabilities held for sale
|
—
|
13,919
|
||||||
|
Total current liabilities
|
263,734
|
296,607
|
||||||
|
Operating lease liabilities
|
57,640
|
58,439
|
||||||
|
Long-term debt
|
204,187
|
363,613
|
||||||
|
Other liabilities
|
74,512
|
97,475
|
||||||
|
Long-term liabilities held for sale
|
—
|
1,325
|
||||||
|
Total liabilities
|
600,073
|
817,459
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders’ equity
|
||||||||
|
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued
|
91
|
91
|
||||||
|
Additional paid-in capital
|
635,994
|
627,787
|
||||||
|
Treasury stock, at cost – 42.4 million and 40.8 million shares
|
(1,575,059
|
)
|
(1,563,614
|
)
|
||||
|
Accumulated other comprehensive loss
|
(116,105
|
)
|
(124,758
|
)
|
||||
|
Retained earnings
|
1,860,319
|
1,711,949
|
||||||
|
Total stockholders’ equity
|
805,240
|
651,455
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
1,405,313
|
$
|
1,468,914
|
||||
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 10
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Revenue Growth Rates Excluding Mavely to GAAP Revenue Growth Rates
(in thousands)
|
Fourth Quarter
|
Full Year
|
|||||||
|
2024 Revenue
|
$
|
445,552
|
$
|
1,732,084
|
||||
|
Less: Mavely 2024 Revenue
|
32,252
|
69,620
|
||||||
|
Adjusted 2024 Revenue
|
$
|
413,300
|
$
|
1,662,464
|
||||
|
2025 Revenue
|
$
|
370,320
|
$
|
1,485,159
|
||||
|
Revenue Growth Rate
|
(16.9
|
)%
|
(14.3
|
)%
|
||||
|
Revenue Growth Rate, excluding Mavely
|
(10.4
|
)%
|
(10.7
|
)%
|
||||
NU SKIN ENTERPRISES, INC.
Reconciliation of Gross Margin Excluding Impact of Inventory Write-off to GAAP Gross Margin
(in thousands)
|
Three months ended
December 31,
|
Year ended
December 31,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Gross Profit
|
$
|
261,981
|
$
|
279,147
|
$
|
1,031,398
|
$
|
1,181,851
|
||||||||
|
Impact of inventory write-off
|
-
|
38,765
|
-
|
38,765
|
||||||||||||
|
Adjusted Gross Profit
|
$
|
261,981
|
$
|
317,912
|
$
|
1,031,398
|
$
|
1,220,616
|
||||||||
|
Gross Margin
|
70.7
|
%
|
62.7
|
%
|
69.4
|
%
|
68.2
|
%
|
||||||||
|
Gross Margin, excluding inventory write-off impact
|
70.7
|
%
|
71.4
|
%
|
69.4
|
%
|
70.5
|
%
|
||||||||
|
Revenue
|
$
|
370,320
|
$
|
445,552
|
$
|
1,485,159
|
$
|
1,732,084
|
||||||||
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 11
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Core Nu Skin Business Gross Margin Excluding Impact of Inventory Write-off to GAAP Gross Margin
(in thousands)
|
Three months ended
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Gross Profit
|
$
|
249,869
|
$
|
244,754
|
||||
|
Impact of inventory write-off
|
-
|
32,704
|
||||||
|
Adjusted Gross Profit
|
$
|
249,869
|
$
|
277,458
|
||||
|
Gross Margin
|
77.6
|
%
|
67.5
|
%
|
||||
|
Gross Margin, excluding inventory write-off impact
|
77.6
|
%
|
76.6
|
%
|
||||
|
Revenue
|
$
|
321,801
|
$
|
362,449
|
||||
NU SKIN ENTERPRISES, INC.
Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin
(in thousands)
|
Three months ended
December 31,
|
Year ended December 31,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Operating (loss) income
|
$
|
23,244
|
$
|
(53,081
|
)
|
$
|
65,763
|
$
|
(151,585
|
)
|
||||||
|
Impact of inventory write-off
|
-
|
38,765
|
-
|
38,765
|
||||||||||||
|
Impact of other charges(1)
|
-
|
2,940
|
7,966
|
2,940
|
||||||||||||
|
Impact of restructuring and impairment
|
-
|
45,876
|
25,114
|
202,360
|
||||||||||||
|
Adjusted operating income
|
$
|
23,244
|
$
|
34,500
|
$
|
98,843
|
$
|
92,480
|
||||||||
|
Operating margin
|
6.3
|
%
|
(11.9
|
)%
|
4.4
|
%
|
(8.8
|
)%
|
||||||||
|
Operating margin, excluding certain charges
|
6.3
|
%
|
7.7
|
%
|
6.7
|
%
|
5.3
|
%
|
||||||||
|
Operating margin growth
|
152.9 |
% |
150.0 |
% |
||||||||||||
|
Operating margin growth (decline), excluding certain charges
|
(18.2 |
)% |
26.4 | % |
||||||||||||
| |
|
|||||||||||||||
|
Revenue
|
$
|
370,320
|
$
|
445,552
|
$
|
1,485,159
|
$
|
1,732,084
|
||||||||
(1) Other charges consist of expenses incurred during the first quarter of 2025 in connection with the Mavely sale, including $2.7 million of
transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units. Other charges for the fourth quarter and full year 2024 consist of transaction-related expenses
incurred related to the sale of Mavely.
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 12
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Effective Tax Rate Excluding Impact of Mavely Gain and Certain Charges to GAAP Effective Tax Rate
(in thousands)
|
Three months ended
December 31,
|
Year ended December 31,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Provision (benefit) for income taxes
|
$
|
3,700
|
$
|
(21,697
|
)
|
$
|
35,993
|
$
|
(28,457
|
)
|
||||||
|
Impact of inventory write-off on provision for income taxes
|
-
|
14,643
|
14,643
|
|||||||||||||
|
Impact of other charges on provision for income taxes
|
-
|
632
|
725
|
632
|
||||||||||||
|
Impact of restructuring and impairment on provision for income taxes
|
-
|
17,329
|
5,433
|
40,399
|
||||||||||||
|
Impact of gain on Mavely sale on provision for income taxes
|
-
|
-
|
(31,104
|
)
|
-
|
|||||||||||
|
Impact of gain on unrealized investment loss on provision for income taxes
|
-
|
-
|
6,074
|
-
|
||||||||||||
|
Provision for income taxes, excluding impact of certain charges
|
$
|
3,700
|
$
|
10,907
|
$
|
17,121
|
$
|
27,217
|
||||||||
|
Income (loss) before provision for income taxes
|
18,191
|
(57,802
|
)
|
196,197
|
(175,051
|
)
|
||||||||||
|
Impact of inventory-write off
|
-
|
38,765
|
-
|
38,765
|
||||||||||||
|
Impact of other charges(1)
|
-
|
2,940
|
7,966
|
2,940
|
||||||||||||
|
Impact of restructuring and impairment expense:
|
-
|
45,876
|
25,114
|
202,360
|
||||||||||||
|
Impact of gain on Mavely sale
|
-
|
-
|
(176,162
|
)
|
-
|
|||||||||||
|
Impact of unrealized investment loss
|
-
|
-
|
28,077
|
-
|
||||||||||||
|
Income before provision for income taxes, excluding impact certain charges
|
$
|
18,191
|
$
|
29,779
|
$
|
81,192
|
$
|
69,014
|
||||||||
|
Effective tax rate
|
20.3
|
%
|
37.5
|
%
|
18.3
|
%
|
16.3
|
%
|
||||||||
|
Effective tax rate, excluding impact of certain charges
|
20.3
|
%
|
36.6
|
%
|
21.1
|
%
|
39.4
|
%
|
||||||||
|
Nu Skin Enterprises Reports Fourth Quarter and 2025 Financial Results
|
page 13
|
NU SKIN ENTERPRISES, INC.
Reconciliation of Earnings Per Share Excluding Impact of Mavely Gain and Certain Charges to GAAP Earnings Per Share
(in thousands, except for per share amounts)
|
Three months ended
December 31,
|
Year ended December 31,
|
|||||||||||||||
|
2025
|
2024
|
2025
|
2024
|
|||||||||||||
|
Net income (loss)
|
$
|
14,491
|
$
|
(36,105
|
)
|
$
|
160,204
|
$
|
(146,594
|
)
|
||||||
|
Impact of inventory write-off
|
||||||||||||||||
|
Inventory write-off
|
-
|
38,765
|
-
|
38,765
|
||||||||||||
|
Tax impact
|
-
|
(14,643
|
)
|
-
|
(14,643
|
)
|
||||||||||
|
Impact of other charges
|
||||||||||||||||
|
Other charges(1)
|
-
|
2,940
|
7,966
|
2,940
|
||||||||||||
|
Tax impact
|
-
|
(632
|
)
|
(725
|
)
|
(632
|
)
|
|||||||||
|
Impact of restructuring and impairment expense:
|
||||||||||||||||
|
Restructuring and impairment
|
-
|
45,876
|
25,114
|
202,360
|
||||||||||||
|
Tax impact
|
-
|
(17,329
|
)
|
(5,433
|
)
|
(40,399
|
)
|
|||||||||
|
Impact of Mavely sale
|
||||||||||||||||
|
Gain on Mavely sale
|
-
|
-
|
(176,162
|
)
|
-
|
|||||||||||
|
Tax impact
|
-
|
-
|
31,104
|
-
|
||||||||||||
|
Impact of unrealized investment loss
|
||||||||||||||||
|
Unrealized investment loss
|
-
|
-
|
28,077
|
-
|
||||||||||||
|
Tax impact
|
-
|
-
|
(6,074
|
)
|
-
|
|||||||||||
|
Adjusted net income
|
$
|
14,491
|
$
|
18,872
|
$
|
64,071
|
$
|
41,797
|
||||||||
|
Diluted earnings per share
|
$
|
0.29
|
$
|
(0.73
|
)
|
$
|
3.18
|
$
|
(2.95
|
)
|
||||||
|
Diluted earnings per share, excluding impact of certain charges
|
$
|
0.29
|
$
|
0.38
|
$
|
1.27
|
$
|
0.84
|
||||||||
|
Diluted earnings per share growth
|
139.7 |
% |
207.8 |
% |
||||||||||||
|
Diluted earnings per share growth (decline), excluding impact of certain charges
|
(23.7 | )% | 51.2 | % |
||||||||||||
| |
|
|||||||||||||||
|
Weighted-average common shares outstanding (000)
|
49,912
|
49,712
|
50,301
|
49,662
|
||||||||||||
# # #
CONTACTS:
Media: media@nuskin.com, (801) 345-6397
Investors: investorrelations@nuskin.com, (801) 345-3577
FAQ
How did Nu Skin (NUS) perform financially in full-year 2025?
Nu Skin reported 2025 revenue of $1.49 billion, down 14.3% from 2024, but swung to diluted EPS of $3.18 from a loss of $(2.95). On an adjusted basis, EPS was $1.27 versus $0.84 a year earlier, reflecting stronger margins and fewer restructuring charges.
What were Nu Skin (NUS) fourth-quarter 2025 results versus 2024?
In Q4 2025, Nu Skin generated revenue of $370.3 million, a 16.9% decline from $445.6 million in Q4 2024. Diluted EPS improved to $0.29 from a loss of $(0.73), or $0.38 excluding prior-year restructuring and other charges, aided by higher gross margins and lower expenses.
What guidance did Nu Skin (NUS) give for Q1 2026 and full-year 2026?
For Q1 2026, Nu Skin projects revenue of $320–$340 million and EPS of $0.10–$0.20. For full-year 2026, it forecasts revenue of $1.35–$1.50 billion and EPS of $0.80–$1.20, including about a 1% foreign-currency headwind and a projected tax rate of 35%.
How are Nu Skin (NUS) customers, affiliates and sales leaders trending?
For Q4 2025, Nu Skin reported 748,796 customers, down 10% year over year. Paid affiliates fell to 129,311, an 11% decline, while sales leaders decreased to 30,045, down 19%. These declines spanned major regions including Mainland China, South Korea and Europe & Africa.
What role did the Mavely sale play in Nu Skin’s 2025 results?
Nu Skin recorded a $176.2 million gain on the Mavely sale in 2025, significantly boosting reported earnings. The company also adjusts metrics to exclude Mavely 2024 revenue, showing 2025 revenue down 10.7% instead of 14.3%, and provides non-GAAP EPS excluding the gain and related charges.
What strategic growth initiatives did Nu Skin (NUS) highlight for 2026?
Nu Skin emphasized its Prysm iO intelligent wellness platform and expansion into India. Over 20,000 Prysm iO devices are already with sales leaders, generating more than 700,000 scans. Management is conducting pre-market activities in India, targeting a fuller market opening in the back half of 2026.
Filing Exhibits & Attachments
4 documents
Nu Skin Enter
NYSE:NUS
NUS Rankings
NUS Latest News
Feb 12, 2026
Nu Skin Enterprises Announces Quarterly Dividend
NUS Latest SEC Filings
Feb 12, 2026
[10-K] NU SKIN ENTERPRISES, INC. Files Annual Report
NUS Stock Data
497.74M
46.44M
2.16%
74.97%
3.89%
Household & Personal Products
Wholesale-drugs, Proprietaries & Druggists' Sundries
United States
PROVO